Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetravalent Live Attenuated Dengue Vaccine in Infants
NCT00322049Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Feb 2004
- Primary completion
- Jun 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of DEN vaccine F17 in dengue fever (3 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Reactogenicity in Terms of Solicited Symptoms After Dose 1, Geometric Mean Titers for N Antibody to All Four Serotypes and JE Vaccine and 2 more. Started Feb 2004; status: completed.
02
Drugs
DEN vaccine F17
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00322049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322049.